Correction: Study on the mechanism of 18β-glycyrrhetinic acid inhibiting the proliferation of renal cancer cells by inducing autophagy through the miR-27a-5p/LC3 axis - Scorecard - MDSpire

Correction: Study on the mechanism of 18β-glycyrrhetinic acid inhibiting the proliferation of renal cancer cells by inducing autophagy through the miR-27a-5p/LC3 axis

  • By

  • Shumin Jia

  • Lei Zhang

  • Yahong Li

  • Duojie Xu

  • Yi Yang

  • Ziying Zhou

  • Wenjing Liu

  • Jianan Zhao

  • Ling Yuan

  • Yi Nan

  • May 13, 2026

Share

Clinical Scorecard: Correction: Investigation into the Role of 18β-glycyrrhetinic Acid in Suppressing Renal Cancer Cell Growth via Autophagy Induction through the miR-27a-5p/LC3 Pathway

At a Glance

CategoryDetail
ConditionRenal Cancer
Key MechanismsAutophagy induction via the miR-27a-5p/LC3 pathway
Target PopulationPatients with renal cancer
Care SettingOncology

Key Highlights

  • 18β-glycyrrhetinic acid suppresses renal cancer cell growth
  • Mechanism involves autophagy induction
  • Involves the miR-27a-5p/LC3 signaling axis
  • Correction issued for figure misplacement
  • Study published in Frontiers in Oncology

Guideline-Based Recommendations

Diagnosis

  • Consider renal cancer diagnosis in patients with relevant symptoms.

Management

  • Utilize 18β-glycyrrhetinic acid as a potential therapeutic agent.

Monitoring & Follow-up

  • Monitor autophagy markers in renal cancer treatment.

Risks

  • Evaluate potential side effects of 18β-glycyrrhetinic acid.

Patient & Prescribing Data

Individuals diagnosed with renal cancer

18β-glycyrrhetinic acid may enhance treatment outcomes through autophagy.

Clinical Best Practices

  • Ensure accurate figure representation in published studies.
  • Regularly review and update clinical data as necessary.
  • Incorporate autophagy modulation strategies in renal cancer management.

Related Resources & Content

Original Source(s)

Correction: Study on the mechanism of 18β-glycyrrhetinic acid inhibiting the proliferation of renal cancer cells by inducing autophagy through the miR-27a-5p/LC3 axis

  • by Shumin Jia, Lei Zhang, Yahong Li, Duojie Xu, Yi Yang, Ziying Zhou, Wenjing Liu, Jianan Zhao, Ling Yuan, Yi Nan

  • May 13, 2026

Related Content

Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2alpha inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.

  • by

  • June 12, 2026

  • 3 min
Systematic pan-cancer analysis reveals context-dependent prognostic and immunological roles of WDR1 with divergent effects in renal and gastric cancers

This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark

REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR

  • May 25, 2026

  • 7 min